Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Niclosamide Injectable in Healthy Volunteers
NCT04592835Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of niclosamide in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 35 days. Status: unknown.
02
Drugs
niclosamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04592835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592835.